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Abstract
Background: The anaplastic lymphoma kinase (ALK) gene is frequently involved in translocations that lead to gene 
fusions in a variety of human malignancies, including lymphoma and lung cancer. Fusion partners of ALK include NPM, 
EML4, TPM3, ATIC, TFG, CARS, and CLTC. Characterization of ALK fusion patterns and their resulting clinicopathological 
profiles could be of great benefit in better understanding the biology of lung cancer.
Results: RACE-coupled PCR sequencing was used to assess ALK fusions in a cohort of 103 non-small cell lung 
carcinoma (NSCLC) patients. Within this cohort, the EML4-ALK fusion gene was identified in 12 tumors (11.6%). Further 
analysis revealed that EML4-ALK was present at a frequency of 16.13% (10/62) in patients with adenocarcinomas, 
19.23% (10/52) in never-smokers, and 42.80% (9/21) in patients with adenocarcinomas lacking EGFR and KRAS 
mutations. The EML4-ALK fusion was associated with non-smokers (P = 0.03), younger age of onset (P = 0.03), and 
adenocarcinomas without EGFR/KRAS mutations (P = 0.04). A trend towards improved survival was observed for 
patients with the EML4-ALK fusion, although it was not statistically significant (P = 0.20). Concurrent deletion in EGFR 
exon 19 and fusion of EML4-ALK was identified for the first time in a Chinese female patient with an adenocarcinoma. 
Analysis of ALK expression revealed that ALK mRNA levels were higher in tumors positive for the EML-ALK fusion than in 
negative tumors (normalized intensity of 21.99 vs. 0.45, respectively; P = 0.0018). However, expression of EML4 did not 
differ between the groups.
Conclusions: The EML4-ALK fusion gene was present at a high frequency in Chinese NSCLC patients, particularly in 
those with adenocarcinomas lacking EGFR/KRAS mutations. The EML4-ALK fusion appears to be tightly associated with 
ALK mRNA expression levels. RACE-coupled PCR sequencing is a highly sensitive method that could be used clinically 
for the identification of EML4-ALK-positive patients.
Background
The anaplastic lymphoma kinase (ALK) gene encodes a
receptor tyrosine kinase (RTK) that has been discovered
to be present in a number of fusion proteins consisting of
the intracellular kinase domain of ALK and the amino-
terminal portions of different genes [1,2]. Activated ALK
is involved in the inhibition of apoptosis and the promo-
tion of cellular proliferation through activation of down-
stream PI3K/Akt and MAPK signalling pathways [3].
Genetic alterations involving ALK, including gene
fusions, amplification, and mutations, have been identi-
fied in anaplastic large cell lymphomas, inflammatory
myofibroblastic tumors, and neuroblastoma, respectively
[1,4-7]. To date, in studies from a variety of human cancer
types, the reported fusion partners of ALK have included
NPM [1], EML4 [8], MSN [9], TPM3 [10,11], ATIC [12-
14], TFG [15], CARS [16], CLTC [17], and KIF5B [18]. In
lung cancer, the primary ALK fusion detected was identi-
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fied as EML4-ALK, followed by TFG-ALK  and  KIF5-
ALK, although other unknown fusions may also exist
which can not be detected due to limits of present tech-
nology [19].
The ALK-EML4 fusion attaches the ALK gene to a gene
involved in microtubule formation and stabilization,
"echinoderm microtubule associated protein-like 4"
(EML4) [20,21]. This fusion generates a transforming
fusion tyrosine kinase, several isoforms of which have
been identified in lung cancers [8,22]. The frequency of
the EML4-ALK fusion was first reported by Soda et al. to
be approximately 6.7% (5/75) in non-small cell lung carci-
nomas (NSCLCs) in Japanese patients [8]. ALK  and
EML4 are both located on the short arm of chromosome
2, separated by 12 megabases (Mb) of sequence, and are
oriented in opposite directions. To date, more than nine
different variants of the EML4-ALK  fusion have been
identified. These variants consist of exons 20 to 29 of
ALK fused to EML4 exon 13 (variant 1, V1), exon 20 (V2),
exon 6 (V3a), exon 6 with an 11 amino acid (aa) insertion
(V3b), exon 14 with an additional 11 nucleotide insertion
of unknown origin at nucleotide 50 in exon 20 of ALK
(V4), exon 2 (V5), exon 13 (V6), exon 14 with the fusion
beginning at nucleotide 13 in exon 20 of ALK (V7), exon
15 (primarily also reported as "V4", in this article
depicted as V8), and exon 18 ("V5", accordingly here as
V9), as described in detail in Horn and Pao's review [23].
ALK gene fusions have been demonstrated to be onco-
genic in 3T3 and Ba/F3 cellular models [24]. Although
different variants of EML4-ALK fusion proteins may
exhibit different enzymatic activities, EML4 retains the
N-terminal coil-coiled domain (CC) in all EML4-ALK
variants. This domain has been shown to be responsible
for the dimerization and constitutive activation of EML4-
ALK [24]. Importantly, in some cell lines harboring
EML4-ALK  fusions, targeting of ALK using specific
inhibitors has shown promising efficacy for treatment of
lung cancer through inhibition of Akt and induction of
apoptosis. For this reason, ALK inhibitors have been
developed and assessed in early clinical trials [25,26].
Published studies using reverse transcriptase-poly-
merase chain reaction (RT-PCR) analysis or fluorescent
in situ hybridization (FISH) to characterize EML4-ALK
fusions in lung cancer have revealed frequencies ranging
from 0.5% to 7.5% in general lung cancer patients and a
frequency of 13.5% in clinical factor-enriched cases [23],
[27,28]. Here, we report the development of a technology
based on rapid amplification of cDNA ends (RACE)-cou-
pled PCR and sequencing to analyze expression of ALK
fusion genes. This technology was designed to identify
both known and novel fusion partners of ALK, followed
by confirmation using qualitative specific RT-PCR. Using
this method, we analysed the ALK fusion status in clinical
lung cancer samples. Results from this study could, thus,
provide a better understanding of ALK fusions with all
potential partner genes in a clinical population. Further-
more, these results provide insight into the clinicopatho-
logical characteristics of ALK  fusion-positive Chinese
NSCLC patients.
Results
Identification of EML4-ALK fusions in 103 cases of NSCLC
RNA samples from a total of 103 NSCLC cases were
reverse-transcribed to make cDNA, followed by oligo-dC
tailing. Two successive rounds of PCR were used to iden-
tify potential fusion fragments (Fig. 1A, B). BigDye3.1-
labeled products were then sequenced to identify fusions
between ALK and potential partners (Fig. 1C). Based on a
sequence alignment with the ALK  reference sequence
(NCBI accession number: NM_004304.3), in total, 12
samples were identified as ALK fusion-positive (Table 1).
RT-PCR confirmation of expression of ALK fusion transcripts 
in positive samples
Fusion gene-specific primers were designed, and qualita-
tive RT-PCR was conducted to confirm the presence of
ALK fusions in positive samples identified by RACE-cou-
pled PCR sequencing. Fusion RNAs from the 12 ALK
fusion-positive samples were amplified by RT-PCR, and
Table 1: EML4-ALK fusion variants identified in the 12 NSCLC cases.
Variant Published fusion type* No. of positive samples Frequency
V1 EML4 E13-ALK E20 4 3.9%
V2 EML4 E20-ALK E20 1 1.0%
V3a EML4 E6-ALK E20 3 2.9%
V3b EML4 E6-11 aa in INS6-ALK E20
V4 EML4 E15-ALK E20 0 0
V5 EML4 E2-ALK E20 1 1.0%
V6 EML4 E18-ALK E20 3 2.9%
*All fusion types have previously been published.Zhang et al. Molecular Cancer 2010, 9:188
http://www.molecular-cancer.com/content/9/1/188
Page 3 of 12
specific bands corresponding to the expected products
were observed after gel electrophoresis (Fig. 1D).
Correlation of ALK fusion with ALK expression
Gene expression profiling was conducted on clinical sam-
ples using the Affymetrix GeneChip® Human Genome
U133 plus 2.0 technology. Normalized expression intensi-
ties for the ALK and EML4 transcripts were extracted
and plotted versus ALK fusion status (Fig. 2A). ALK was
found to be significantly over-expressed in the 10 fusion-
positive samples analyzed (2 EML4-ALK cases were not
analyzed by microarray), but not in samples lacking ALK
Figure 1 Assessment of ALK fusion status by RACE-coupled PCR sequencing. (A) Representative image showing gel electrophoresis results for 
first-round PCR products. Lane M, marker (200 bp ladder); lanes P, positive controls (2 lanes); lane NTC, no template control; other lanes, samples 1 
through 45. (B) Representative image showing gel electrophoresis results for second-round PCR products. Lane organization is identical to (A). (C) Rep-
resentative sequencing chromatograph showing ALK fusion with EML4. (D) RT-PCR validation for samples positive for ALK fusion expression. RT-PCR 
was used to confirm EML4-ALK fusion transcript expression in 12 samples. Sample 68 is the V5 variant (E2;A20, 408 bp). Samples 268, 171, and 320 are 
V9 variants (E18;A20, 2256 bp). Samples 446, 433, 138, and 347 are V1 variants (E13;A20, 1689 bp). Sample 534 is the V2 variant (E20;A20, 2445 bp). 
Samples 131, 421, and 431 are V3a/b variants (E6;A20 or E6 ins33;A20, 867 and 900 bp, respectively). Lane M, marker (100 bp ladder).
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Figure 2 ALK expression is associated with ALK fusion status. (A) ALK is overexpressed at the mRNA level in 10 fusion-positive cases analyzed us-
ing Affymetrix Genechip® U133 plus 2.0. AP, Adjacent normal tissues; N, Cancer samples with no fusion; Y, Cancer samples positive for fusion. (B) ALK 
is differentially expressed between EML-ALK fusion-positive and negative samples (normalized intensity of 21.99 vs. 0.45, respectively; P = 0.0018), but 
EML4 expression was not significantly different between the groups. Error bars indicate mean ± standard deviation.
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fusions or control adjacent tissues. ALK expression was
significantly different in EML-ALK fusion-positive and -
negative samples (normalized intensity values of 21.99 vs.
0.45, respectively; P = 0.0018). In contrast, EML4 expres-
sion did not differ significantly between the groups (Fig.
2B). These results indicate that presence of the ALK
fusion was strongly associated with ALK mRNA expres-
sion levels, leading to a 50-fold increase in expression.
Concurrent EGFR mutation and ALK fusion in one sample
For all samples analyzed for ALK  fusion, DNA was
obtained for sequencing of the EGFR  gene to assess
mutation status. In one sample, the patient was found to
be heterozygous for 2235-2249 del15 in exon 19 of EGFR
(Fig. 3A). In the same sample, EML4-ALK variant 3b was
also present, in which exons 20 to 29 of ALK were con-
nected to exon 6 of EML4, with an additional 33 bp inser-
tion from intron 6 of EML4 (Fig. 3B, C). Histological
adenocarcinoma was identified in this patient by mor-
phological examination of hematoxylin and eosin-stained
tissue samples (Fig. 3D).
Association of ALK fusion status with clinicopathological 
parameters
Of the 12 samples containing EML4-ALK  fusions, 10
were identified as adenocarcinomas (one of which con-
tained a mixed squamous carcinoma component), and
two were identified as squamous cell carcinomas. In these
patients, the presence of the ALK fusion was mutually
exclusive with the presence of KRAS mutations. Notably,
although the presence of ALK fusions was correlated with
wild-type  EGFR  status (P  = 0.04), we did identify one
patient who had both the EML4-ALK  fusion and an
EGFR mutation.
To our knowledge, this is the first patient identified
with a concurrent EGFR exon 19 deletion and the EML4-
ALK  fusion translocation. The concurrent mutations
occurred in a female, non-smoking Chinese patient with
a histological adenocarcinoma. EML4-ALK was signifi-
cantly associated with non-smoking (P = 0.03). Patients
with  ALK  fusions exhibited a significantly decreased
number of smoking pack-years (5.0 vs. 18.5; P < 0.01) and
were younger (53 vs. 61; P = 0.03) compared with patients
without the fusion gene. No mutation in the kinase
domain of ALK was detected by sequencing samples from
the first group of 50 NSCLC cases collected consecutively
(data not shown). Thus, mutation of ALK  in NSCLC
likely either does not occur or is rare. A trend towards
improved survival was observed in the EML4-ALK
cohort, though this was not statistically significant (P =
0.15; Fig. 4). ALK  fusion-positive NSCLCs exhibited a
hazard ratio of 0.54 (95% CI, 0.23-1.26) for overall sur-
vival.
Discussion
ALK belongs to the insulin receptor subfamily of receptor
tyrosine kinases. Aberrant ALK activity has recently been
shown to be present in anaplastic large cell lymphoma, as
well as in solid tumors, including NSCLC [8,22]. Previous
investigations have shown that translocation of ALK can
result in fusion with the neighbouring gene, EML4, in
cancer cells [19]. The fused genes then encode a fusion
protein in which the intracellular tyrosine kinase domain
of the ALK receptor is constitutively active. In all EML4-
ALK fusion variants, the amino-terminal coiled-coil (CC)
domain of EML4 has been shown to be retained in the
fusion protein and is believed to be responsible for recep-
tor dimerization and constitutive activation of the kinase
domain (Fig. 5).
In the present study, the five transcript variants identi-
fied all possessed the CC domain and are, thus, likely to
produce active, oncogenic EML4-ALK proteins in these
NSCLC tumors. In future studies, we intend to investi-
gate ALK kinase activity and activation of downstream
signalling kinases in patient samples. These studies are
p a r t i c u l a r l y  i m p o r t a n t ,  a s  d a t a  f r o m  S o d a  et al. [8]
revealed that deletion of either the HELP or WD domains
of EML4 can reduce kinase activity, by up to 50%. Thus,
some variants may produce kinases with more activity
than others.
To determine whether ALK fusions exhibit characteris-
tic expression profiles at the mRNA level, we compared
ALK  e x p r e s s i o n  b a s e d  o n  m i c r o a r r a y  d a t a  ( u s i n g  t h e
Affymetrix Genechip® human genome U133 plus 2.0 sys-
tem) that corresponded to the same set of RNA samples.
W e  f o u n d  t h a t  A L K  w a s  e x p r e s s e d  a t  h i g h e r  l e v e l s  i n
samples containing EML4-ALK, compared with samples
that did not contain the fusion. Due to potential errors in
microarray expression data arising from multiple correc-
tion procedures, real-time qRT-PCR should be per-
formed to confirm ALK mRNA expression data.
Additionally, use of immunohistochemistry could also
confirm whether mRNA expression is correlated with
EML4-ALK protein expression.
Careful review of the literature reveals that ALK fusion
proteins are frequently present in lung cancer patients
(Table 2). For example, Soda et al. found that the fre-
quency of EML4-ALK fusion variants 1 and 2 was 6.7%
(5/75) in a Japanese population using RT-PCR [20].
Taheuchi et al. [29] found a frequency of 4.35% (11/253)
for EML4-ALK fusion variants 1-5 in Japanese patients
using RT-PCR. Another RT-PCR-based study, by Koi-
vunen  et al. [30], showed that 3.6% (6/167) of Korean
patients and 1.4% (2/136) of Caucasian patients with lung
cancer possessed EML4-ALK variants 1, 3, and 4. Using a
combination of FISH and RT-PCR, Perner et al. [31]
found that 0.5% (3/603) of Caucasians with lung cancerZhang et al. Molecular Cancer 2010, 9:188
http://www.molecular-cancer.com/content/9/1/188
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Figure 3 Concurrent heterozygous ALK fusion and EGFR deletion in a single adenocarcinoma. (A) Chromatograph indicating a heterozygous 
deletion (2235-2249 del 15) in exon 19 of EGFR in a patient with EML4-ALK. (B) Sequence of EML4-ALK fusion variant 3b. Red sequence indicates exon 
6 of EML4. Green sequence indicates an insertion of 33 bp from intron 6 of EML4 found in variant 3b. Blue sequence indicates exon 20 of ALK. (C) Chro-
matograph for EML4-ALK fusion variant 3b indicating the presence of a heterozygous fusion of ALK with exon 6 of EML4 with an additional 33 bp in-
sertion. (D) Histological staining of the adenocarcinoma from the patient with both an EGFR mutation and EML4-ALK fusion. Scale bar = 100 μm.
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have EML4-ALK variant 1. Wong et al. [32] found that
EML4-ALK variants 1, 2, 3, and 9 (previously as "V5")
were present at a frequency of 4.9% (13/266) in Chinese
patients with lung cancer using RT-PCR. Also using RT-
PCR, Martelli [33] found that 7.5% (9/120) of Italian and
Spanish patients possessed EML4-ALK variants 1 and 3.
In a study by Shaw and colleagues, NSCLC patients were
selected for genetic screening on the basis of two or more
of the following characteristics: female gender, Asian eth-
nicity, never/light smoking history, and adenocarcinoma
histology. Analysis of EML4-ALK  in these patients by
FISH revealed a substantially higher frequency of the
fusion (13%; 19/141) [34]. As is evident in these studies,
RT-PCR and FISH represent the primary methods previ-
ously used to analyze the frequency of ALK fusions (Table
2).
Our data, which was based on non-selective hospital-
obtained samples, revealed a frequency of 11.6% (12/103)
for EML4-ALK fusion variants 1, 2, 3, 5, and 9 in Chinese
NSCLC patients using RACE-coupled PCR sequencing
technology. This rather high frequency of ALK  fusion
may be attributable the high sensitivity of RACE-PCR
sequencing assays. Use of this technique has also con-
firmed that, in non-small cell lung cancer, the fusion of
ALK appears to occur solely with EML4, as previously
reported [35], [36], rather than with other genes.
Comparison of ALK fusion status with results charac-
terizing the presence of EGFR and KRAS mutations in the
same set of cancer samples revealed that ALK  fusions
occurred in the absence of KRAS  mutations. Previous
reports have indicated that ALK fusion can occur concur-
rently with EGFR mutations (1/305) and KRAS mutations
(1/120), although these may be rare events [30,33]. Con-
sistent with these observations, we also identified a
patient with concurrent EGFR  exon 19 deletion and
EML4-ALK fusion. The patient, who was female, non-
smoking, and Chinese with histological adenocarcinoma,
exhibited post-surgery overall survival of more than 38
months. This observation was particularly interesting
because of the abnormality of mutations in two potential
"tumor-driving" receptor genes in a single tumor.
Whether tumor progression is dependent on both
kinases, or only one of the two receptors, is unclear in
this case. Thus, clarification of the actual activation status
of the two receptors is important in assessing the use of
targeted therapies, including EGFR inhibitors and/or
ALK inhibitors. Notably, the frequency of ALK fusions in
patients with adenocarcinomas that did not exhibit
EGFR/KRAS  mutations reached 45.0% (9/21), strongly
indicating that only a specific molecular subset of adeno-
carcinomas is characterized by EML4-ALK fusion. Thus,
stratification of patients with ALK fusions may be useful
in the development of personalized medical treatments
for NSCLC.
Characterization of associations between ALK fusion
status and clinicopathological variables revealed that
EML4-ALK  fusions were associated with adenocarci-
noma, because fusions were identified in nine cases of
adenocarcinoma, two cases of squamous carcinoma, and
one case of adenocarcinoma with partial squamous carci-
noma components. EML4-ALK fusion was also associ-
ated with non-smokers (P  = 0.02), and patients who
possessed the ALK fusion had significantly less smoking
pack-years (6.9 vs. 19.1; P = 0.01). Grouping of patients
revealed that the frequency of the EML4-ALK fusion was
16.13% (10/62) in patients with adenocarcinomas and
19.23% (10/52) in never-smokers. Patients with EML4-
ALK fusions were also significantly younger (53 vs. 61; P
= 0.03) in comparison to patients without the fusion gene.
Results showing that ALK fusion is frequently associated
with adenocarcinoma and younger onset of disease were
consistent with previous reports [37].
Figure 4 Kaplan-Meier survival curve, stratified by ALK fusion sta-
tus. Percent survival of patients with and without ALK fusions was plot-
ted versus the number of months after surgery. Prior to the date of 
article submission, the ALK fusion-positive patients (n = 12) did not 
have enough events to determine the median overall survival, while 
the ALK fusion-negative patients (n = 101) had a median overall survival 
of 50.5 months. The hazard ratio for death in the ALK fusion-positive 
group was 0.54 (95% CI, 0.23-1.26). The log-rank (Mantel-Cox) test had 
a chi-squared value of 2.33 (P = 0.15).
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Figure 5 Structure of the N-terminal exons of EML4. The coiled-coil 
domain (CC) is responsible for dimerization and constitutive activation 
of EML4-ALK; HELP, hydrophobic EMAP-like protein domain; WD, WD-
repeat domain.
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Table 2: ALK fusion variants previously reported in lung cancer.
Citation Freq. Origin Method Number of Positives for each Fusion type
V1 V2 V3 V4 V5 V6 V7 V8 V9
Soda, et al. Nature 2007 6.7%
(5/75)
Japanese RT-PCR 32
Takeuchi et al.
Clin Cancer Res. 2008 
4.35%
(11/253)
Japanese RT-PCR 3331 1
Takeuchi et al.
Clin Cancer Res. 2009 
/J a p a n e s e i A E P / R T - P C R 113 1 1
Koivunen et al.
Clin Cancer Res. 2008 
3.6% (6/167) Korean RT-PCR 24 2
1.4% (2/136) Caucasian
Inamura et al. J Thorac Oncol. 2008 2.3% (5/221) Japanese RT-PCR 23
Perner et al. Neoplasia 2008 0.5% (3/603) Caucasian FISH, RT-PCR 3
Wong et al.
Cancer. 2009 
4.9% (13/266) Chinese RT-PCR 228 1
Martelli et al.
Am J Pathol. 2009 
7.5% (9/120) Italian and Spanish RT-PCR 72
Present study 11.6%
(12/103)
Chinese RACE-coupled PCR sequenc-ing 4 1 3 1 3Zhang et al. Molecular Cancer 2010, 9:188
http://www.molecular-cancer.com/content/9/1/188
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No mutation in ALK was identified by sequencing sam-
ples from 50 NSCLC cases (data not shown). However,
patients in the EML4-ALK  cohort appeared to exhibit
increased survival, compared to patients without the
fusion, although this was not statistically significant (P =
0.15), with a hazard ratio of 0.54 (95% CI, 0.23-1.26) for
overall survival. Considering that mutated EGFR is used
as a prognostic indicator, better prognosis may be associ-
ated with the presence of EML4-ALK fusions in NSCLC,
suggesting that EML4-ALK  may represent an effective
prognostic factor, similar to EGFR.
Recently,  ALK  f u s i o n  w a s  r e p o r t e d  t o  p l a y  a  r o l e  i n
resistance to EGFR tyrosine kinase inhibitors (TKIs) [34].
However, cancers characterized by expression of ALK
fusions are clinically-sensitive to specific ALK inhibitors
[25,26]. Thus, ALK fusions may be useful as biomarkers
for predicting the response to ALK TKI and resistance to
EGFR TKI. Immunohistochemical analysis of ALK
expression could serve as a screening tool and potential
surrogate technique to assess ALK fusion status. Though
the correlation between ALK  gene rearrangement and
EML4-ALK mRNA and protein levels has been disputed
[33], [38], [39], our data suggests that ALK fusion did cor-
relate with increased mRNA expression.
In the present study, patients with ALK fusions did not
receive TKI treatment. However, our results, together
with those from previous studies, indicate that correla-
tions between ALK fusion status and the efficacy of EGFR
TKI and ALK TKI require further investigation in a larger
patient cohort. Concurrent EGFR mutation and EML4-
ALK fusion in one patient in this study (1/12), together
with data from previous reports [30,33], also suggests
t h a t  t r e a t m e n t  e f f i c a cy  s h o u l d  a l s o  be  as s e s s ed  i n  t h i s
group of patients. Given the reported resistance of
tumors with ALK fusions to EGFR TKI, in rare cases with
concurrent ALK fusion and EGFR/KRAS mutation, the
molecular heterogeneity of these altered oncogenes and
potential cross-talk between their protein products
requires further investigation. Results from such studies
would be useful in the development of sequential or con-
current target therapies.
In summary, RACE-coupled PCR sequencing can serve
as sensitive tool to identify ALK fusions with a variety of
potential partners in patient samples. However, in the
present study of NSCLC samples, only EML4 was identi-
fied as a partner protein. A high frequency (11.6%) of
NSCLC samples exhibited expression of different EML4-
ALK  transcript variants. Patients with ALK  fusions
appeared to exhibit a trend towards improved survival in
comparison to patients without fusions. Notably, the
presence of ALK fusions was associated with histological
adenocarcinomas and with wild-type EGFR and  KRAS
status, which may be of clinical relevance in targeted
therapy using ALK inhibitors.
Conclusions
A high frequency of the EML4-ALK  fusion gene was
present in Chinese patients with NSCLC, particularly in
patients with adenocarcinomas without EGFR/KRAS
mutations. ALK fusion status was significantly associated
with ALK mRNA expression levels. RACE-coupled PCR
sequencing was highly sensitive and could serve as a
method for identifying EML4-ALK  fusion patients for
targeted therapies in the clinic.
Methods
Lung cancer patients
In total, 103 NSCLC specimens were obtained from
patients who underwent surgery for NSCLC from 2004 to
2006 at Guangdong General Hospital in the Guangdong
Lung Cancer Institute of the Guangdong Academy of
Medical Sciences. NSCLC samples included 62 adenocar-
cinomas, 29 squamous cell carcinomas, 11 large cell car-
cinomas, and 1 smooth muscle sarcoma.
Informed consent to use resected tissue for genetic
analysis was obtained for all patients. The study was
approved by the Institutional Review Boards (IRBs) of
Guangdong General Hospital.
Demographic and clinicopathological profiles for the
cases are shown in Table 3. Staging and histological clas-
sification were based on the World Health Organization
(WHO) system. All 103 cases were analyzed for ALK
fusion status, and both EGFR/KRAS mutation data and
ALK fusion data were obtained for 96 of the 103 cases.
Nucleic acid extraction
Total RNA and DNA were extracted from lung tissue
samples using the RNeasy kit (QIAGEN, Valencia, CA)
and DNeasy kit (QIAGEN), respectively. All samples
were pathologically assessed and trimmed at low temper-
ature to ensure that more than 80% of the sample con-
sisted of tumor tissue, while protecting the RNA from
degradation. RNA quality was assessed by gel electropho-
resis using an Agilent bio-analyzer 2100 (with RNA integ-
rity number [RIN] > 6). DNA quality was assessed by
routine gel electrophoresis.
ALK fusion analysis by RACE-coupled PCR sequencing
This methodology is based on the principles of 5'-RACE
and RT-PCR. Briefly, an ALK gene-specific primer was
used to reverse transcribe RNAs into cDNAs. The
sequence of the primer was 5'-TTCAGGCAGCGTGT-
TCACAGCCA-3'. Reverse transcription was performed
based on the manufacturer's recommended protocol for
the TaKaRa RNA PCR (AMV) kit, Ver. 3.0 (Takara).
Briefly, the RT reaction consisted of 2 μL MgCl2, 1 μL 10
× RT buffer, 3.75 μL H2O, 1 μL 10 mM dNTPs, 0.25 μL
RNase inhibitor, 0.5 μL AMV, 0.5 μL 12.5 μM gene-spe-
cific primer, and 1 μL RNA (< 500 ng total RNA). TheZhang et al. Molecular Cancer 2010, 9:188
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reaction was incubated at 42°C for 30 min, 99°C for 5
min, and 5°C for 5 min. After reverse transcription,
cDNAs were purified using the High Pure PCR Product
Purification Kit (Roche) according to the manufacturer's
protocol. Purified cDNAs were further subjected to poly-
cytidine (poly-C) tailing. Briefly, reactions containing 1.5
μL 1% BSA, 5.0 μL 5 × tailing buffer, 2.5 μL 2 mM dCTP,
and 15.0 μL purified cDNA were gently mixed and incu-
bated for 2-3 min at 94°C, followed by incubation for 2
min on ice. After the addition of 1 μL TdT, the reactions
were incubated for an additional 30 min at 37°C. TdT was
then inactivated by incubation at 65°C for 10 min, and the
contents of the reaction were collected by brief centrifu-
gation and placed on ice.
Two PCR reactions were performed to amplify target
cDNA fragments spanning exon 20 of ALK and upstream
sequences that may contain transcript sequences for any
genes fused to ALK. Primers for the first and PCR reac-
tions were as follows: forward primer 5'-GGCCA CGC
GTCCACTAGTACGGGGGGGGGG-3' and reverse
primer 5'-GGCACCTCCTTCAC GTCACTGATG-3'
and forward primer 5'-GGCCAC GCGTCGA CTAG-
TAC-3' and reverse primer 5'-ACCAGGAAACAGCTAT
GACCGGTCTTG CCAGCAAAGCAGTAG TTG -3',
respectively. PCR reactions were performed according to
the manufacturer's instructions for the HS PCR kit
(Takara). PCR products were then purified and labelled
using the BDT v3.1 Ready Reaction-5000 and SEQ Buffer
5000 Ready Reaction (Applied Biosystems) using the M13
sequencing primer, 5'-CAGGAAACAGCT ATGACC-3'.
Sequencing was performed on a Genetic Analyzer
3730XL (Applied Biosystems). Target sequences of inter-
est were aligned with the ALK  reference sequence
(NM_004304.3) to determine if a fusion with another
gene was present.
EGFR mutation analysis by direct sequencing
Genomic DNA from each sample was used for sequence
analysis of EGFR exons 18, 19, 20, and 21. These exons
were amplified by PCR as previously reported [40], and
the resulting PCR products were purified and labelled for
Table 3: Summary of patient demographic and clinicopathological profiles.
Characteristic Number of Patients ALK fusion
Positive Negative P-value
No. of patients 103 12 (11.6%) 91
Age (years; mean ± SD) 52 (< 61 y) 8 44 0.37
53 (≥ 61 y) 4 39
Gender
Male 74 (71.8%) 7 67 0.27
Female 29 (28.2%) 5 24
Smoking
Smokers 51 (49.5%) 2 47 0.03
Non-smokers 52 (50.5%) 10 44
Histology
Adenocarcinoma 62 (60.2%) 10 52 0.08*
Squamous cell 29 (28.1%) 2 27
carcinoma 11 (10.7%) 0 11
Large-cell 1 (1.0%) 0 1
carcinoma
Others
Stage
I 63 (61.2%) 8 55 0.72
II 18 (17.5%) 1 17
III 20 (19.4%) 3 17
IV 2 (1.9%) 0 2
* AC compared with combined SCC, LCC, and other histological types.Zhang et al. Molecular Cancer 2010, 9:188
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sequencing according to the manufacturer's protocol for
the BigDye 3.1 kit (Applied Biosystems).
Statistical analyses
Statistical analysis of associations between ALK  fusion
status and clinical factors was performed using the chi-
squared test or Fisher's exact test. Student's t-test was
used for comparisons between means. Pearson's correla-
tion coefficient was calculated when assessing relation-
ships between continuous variables. Kaplan-Meier
survival curves were generated and the log-rank test was
used to test the significance of differential survival. P val-
ues less than 0.05 were deemed to indicate statistical sig-
nificance.
Note
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